New scan could spot hidden aggressive prostate cancer in men who think They're safe
NCT ID NCT05852041
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests whether a special PET-MRI scan using a radioactive tracer called rhPSMA-7.3 can find higher-risk prostate cancer that standard tests might miss. Men with low-risk or favorable intermediate-risk prostate cancer who are candidates for active surveillance will receive the scan before a prostate biopsy. The goal is to see if the scan better identifies those who actually need treatment rather than just monitoring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flotufolastat F-18 Gallium (rhPSMA-7.3)
What this could lead to
If successful, this imaging method could help identify men who need immediate treatment rather than active surveillance, potentially catching aggressive prostate cancer earlier.
What could go wrong
This is a small early-phase pilot study, so results may not apply broadly. The radioactive tracer may not reliably distinguish aggressive from slow-growing cancers, and there are risks from radiation exposure and biopsy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- ENLIGHTEN Trial: POSLUMA PET/CT for Prostate Can NCT06813898
- Focal Ablation for Prostate Cancer Trial (NCT06178354)
- CV CARE: Heart Health in Prostate Cancer ADT (NCT06202820)
- OCEAN Trial: PSMA-Directed Radiation for Prostat NCT06392295
- Prostate Cancer Trial: Lu-PSMA & Hormone Therapy NCT07650240
- Study of Double-Positive Cells in Metastatic Can NCT06967961
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact